Disetronic, Type 2 Diabetes In MiniMed's Sights Following Medtronic Merger
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's international marketing infrastructure provides a platform for MiniMed to expand its presence in the overseas diabetes care market and an opportunity to challenge the dominance of Disetronic in Europe. Medtronic agreed to acquire MiniMed for $3.28 bil. on May 30.
You may also be interested in...
People In Brief
Vasogen names CEO: Board Chairman Terry Gregg succeeds David Elsley as CEO March 7. Gregg will leverage former experience as chief operating officer of Medtronic MiniMed to guide the commercialization of Vasogen's Celacade immune modulation therapy for peripheral arterial disease and chronic heart failure. Gregg is credited for his role in Medtronic's $3.4 billion acquisition of MiniMed in 2001 (1"The Gray Sheet" June 4, 2001, p. 5). He also has served in executive roles at Smith & Nephew and Allergan and serves on the boards of DexCom, LMS Medical Systems and Patton Medical Devices. Elsley, who founded Vasogen, will remain a member of the board of directors and Gregg retains his post as board chairman. Vasogen is preparing to meet with FDA regarding the regulatory pathway for Celacade, which showed a 39% reduction in the risk of first cardiovascular hospitalization or death in New York Heart Association Class II patients in the 2,408-patient Acclaim trial (2"The Gray Sheet" Sept. 11, 2006, p. 8)...
People In Brief
Vasogen names CEO: Board Chairman Terry Gregg succeeds David Elsley as CEO March 7. Gregg will leverage former experience as chief operating officer of Medtronic MiniMed to guide the commercialization of Vasogen's Celacade immune modulation therapy for peripheral arterial disease and chronic heart failure. Gregg is credited for his role in Medtronic's $3.4 billion acquisition of MiniMed in 2001 (1"The Gray Sheet" June 4, 2001, p. 5). He also has served in executive roles at Smith & Nephew and Allergan and serves on the boards of DexCom, LMS Medical Systems and Patton Medical Devices. Elsley, who founded Vasogen, will remain a member of the board of directors and Gregg retains his post as board chairman. Vasogen is preparing to meet with FDA regarding the regulatory pathway for Celacade, which showed a 39% reduction in the risk of first cardiovascular hospitalization or death in New York Heart Association Class II patients in the 2,408-patient Acclaim trial (2"The Gray Sheet" Sept. 11, 2006, p. 8)...
Medtronic MiniMed Consumer CGMS PMA Supplement To Be Refiled In Dec.
Medtronic MiniMed's proposed labeling for the consumer version of its continuous glucose monitoring system (CGMS) "will not be as aggressive" as the firm originally planned, President Terry Gregg said Sept. 25 at an institutional investor conference in Minneapolis.